About 5,000 lawsuits are pending, including some from patients crippled by tiny particles of metallic debris
The DePuy orthopedic division of Johnson & Johnson, citing declining sales, began phasing out both models of the device — formally known as an articular surface replacement device, which DePuy marketed under the name ASR — in November 2009 and formally recalled them in August 2010 amid reports in databases of orthopedic patients abroad showing they were failing prematurely at high rates.
But in a confidential letter, the F.D.A. told Johnson & Johnson in August 2009 that company studies and clinical data submitted to gain approval in the United States to sell the model available overseas were inadequate to determine the implant’s safety and effectiveness, according to a summary of the letter reviewed by The New York Times.
New guidelines for managing cholesterol call for more aggressive prevention and earlier treatment, including a recommendation...
More than 100 substances widely used in common US foods, supplements and beverages underwent no health...
